We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only cements its prospects in the field.